. 2010 Jun;7(7).
doi: 10.1038/nrclinonc.2010.84.

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use

Charles Ferté 1 Fabrice André  Jean-Charles Soria  
  • PMID: 20551944
  •     121 References
  •     46 citations


The explosion of knowledge in cancer biology in the past two decades has led to the identification of specific molecular circuits in solid tumors. These pathways reflect specific abnormalities thought to drive malignant progression. This knowledge has also generated a vast panel of cancer biomarkers although many of these biomarkers lack sufficient research and validation to be used in the clinic. This Review discusses relevant molecular prognostic and/or predictive biomarkers in the six leading tumors with the highest contribution to cancer mortality: breast, lung, colorectal, prostate, pancreatic and ovarian cancer. Each biomarker is described according to its associated clinicopathological presentation and specific associated molecular interactions. Despite only few biomarkers being currently implemented in clinical practice, a new generation of predictors is emerging that could modify the classic organ-based cancer classification (for example, defects in DNA repair, aberrant MAPK signaling and aberrant PI3K/Akt/mTOR signaling). The advent of high-throughput strategies will also probably substitute monobiomarker strategies.

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Ioannis Boukovinas, Chara Papadaki, +10 authors, John Souglakos.
PLoS One, 2008 Nov 13; 3(11). PMID: 19002265    Free PMC article.
Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives.
J P Spano, R Fagard, +3 authors, G Milano.
Ann Oncol, 2005 Jan 26; 16(2). PMID: 15668269
Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.
Wade S Samowitz, Hans Albertsen, +5 authors, Martha L Slattery.
J Natl Cancer Inst, 2006 Dec 07; 98(23). PMID: 17148775
Highly Cited.
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
Veronika Auner, Gernot Kriegshäuser, +4 authors, Robert Zeillinger.
BMC Cancer, 2009 Apr 11; 9. PMID: 19358724    Free PMC article.
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Maurizio Scaltriti, Sarat Chandarlapaty, +15 authors, José Baselga.
Clin Cancer Res, 2010 Apr 22; 16(9). PMID: 20406840    Free PMC article.
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Frédérique Penault-Llorca, Fabrice André, +11 authors, Henri Roché.
J Clin Oncol, 2009 Apr 22; 27(17). PMID: 19380452
Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
Victor R Grann, Andrea B Troxel, +3 authors, Alfred I Neugut.
Cancer, 2005 Apr 22; 103(11). PMID: 15844176
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
Helena Linardou, Issa J Dahabreh, +5 authors, Samuel Murray.
Lancet Oncol, 2008 Sep 23; 9(10). PMID: 18804418
Highly Cited. Systematic Review.
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
Johann S de Bono, Howard I Scher, +7 authors, Derek Raghavan.
Clin Cancer Res, 2008 Oct 03; 14(19). PMID: 18829513
Highly Cited.
Barriers to Integrating Gene Profiling for Stage II Colon Cancer.
Scott Kopetz, James L Abbruzzese.
Clin Cancer Res, 2009 Dec 10; 15(24). PMID: 19996205
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
Shuji Ogino, Katsuhiko Nosho, +5 authors, Charles S Fuchs.
Gut, 2008 Oct 04; 58(1). PMID: 18832519    Free PMC article.
Highly Cited.
Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Julia Willner, Kaitlyn Wurz, +4 authors, Elizabeth M Swisher.
Hum Pathol, 2007 Jan 30; 38(4). PMID: 17258789
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
Arnab Chakravarti, Michelle DeSilvio, +9 authors, Radiation Therapy Oncology Group.
J Clin Oncol, 2007 Jul 20; 25(21). PMID: 17634487    Free PMC article.
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Maisa Yoshimoto, Anthony M Joshua, +6 authors, Jeremy A Squire.
Mod Pathol, 2008 May 27; 21(12). PMID: 18500259
Highly Cited.
REporting recommendations for tumor MARKer prognostic studies (REMARK).
Lisa M McShane, Douglas G Altman, +4 authors, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
Nat Clin Pract Oncol, 2005 Sep 01; 2(8). PMID: 16130938
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
D F Hayes, R C Bast, +10 authors, R J Winn.
J Natl Cancer Inst, 1996 Oct 16; 88(20). PMID: 8841020
Highly Cited. Review.
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Primo N Lara, Karen Giselle Chee, +8 authors, David R Gandara.
Cancer, 2004 May 13; 100(10). PMID: 15139054
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
Christine Desmedt, Fanny Piette, +18 authors, TRANSBIG Consortium.
Clin Cancer Res, 2007 Jun 05; 13(11). PMID: 17545524
Highly Cited.
What should physicians look for in evaluating prognostic gene-expression signatures?
Jyothi Subramanian, Richard Simon.
Nat Rev Clin Oncol, 2010 Apr 28; 7(6). PMID: 20421890
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, +7 authors, Martin E Gore.
J Clin Oncol, 2008 Oct 29; 26(34). PMID: 18955455
Highly Cited.
Molecular classification of neoplasms of the pancreas.
Ralph H Hruban, N Volkan Adsay.
Hum Pathol, 2009 Apr 14; 40(5). PMID: 19362631
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Fred R Hirsch, Marileila Varella-Garcia, +16 authors, Brian Holloway.
J Clin Oncol, 2006 Nov 01; 24(31). PMID: 17075123
Highly Cited.
PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Iwona K Kolasa, Alina Rembiszewska, +6 authors, Jolanta Kupryjanczyk.
Cancer Biol Ther, 2008 Nov 26; 8(1). PMID: 19029838
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
Robert J Kurman, Ie-Ming Shih.
Int J Gynecol Pathol, 2008 Mar 05; 27(2). PMID: 18317228    Free PMC article.
Highly Cited. Review.
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
D J Grignon, R Caplan, +10 authors, J D Cox.
J Natl Cancer Inst, 1997 Jan 15; 89(2). PMID: 8998185
Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.
Martin Lubin, Adam Lubin.
PLoS One, 2009 May 30; 4(5). PMID: 19478948    Free PMC article.
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
N Lynn Henry, Daniel F Hayes.
Oncologist, 2006 Jun 24; 11(6). PMID: 16794234
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
Amanda Blackford, Oscar K Serrano, +22 authors, Ralph H Hruban.
Clin Cancer Res, 2009 Jul 09; 15(14). PMID: 19584151    Free PMC article.
Highly Cited.
TMPRSS2-ERG and PTEN loss in prostate cancer.
Jeremy A Squire.
Nat Genet, 2009 Apr 29; 41(5). PMID: 19399032
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Kanishka Sircar, Maisa Yoshimoto, +10 authors, Jeremy A Squire.
J Pathol, 2009 Apr 30; 218(4). PMID: 19402094
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
Carlos Gomez-Roca, Christophe M Raynaud, +10 authors, Jean-Charles Soria.
J Thorac Oncol, 2009 Aug 19; 4(10). PMID: 19687761
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Arnaud D Roth, Sabine Tejpar, +14 authors, Fred Bosman.
J Clin Oncol, 2009 Dec 17; 28(3). PMID: 20008640
Highly Cited.
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Brett S Carver, Jennifer Tran, +10 authors, Pier Paolo Pandolfi.
Nat Genet, 2009 Apr 28; 41(5). PMID: 19396168    Free PMC article.
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Yohann Loriot, Pierre Mordant, +2 authors, Jean-Charles Soria.
Nat Rev Clin Oncol, 2009 Jul 15; 6(9). PMID: 19597509
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Ken A Olaussen, Ariane Dunant, +14 authors, IALT Bio Investigators.
N Engl J Med, 2006 Sep 08; 355(10). PMID: 16957145
Highly Cited.
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
J Boyd, Y Sonoda, +11 authors, W J Hoskins.
JAMA, 2000 May 12; 283(17). PMID: 10807385
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
Zhong Zheng, Tingan Chen, +3 authors, Gerold Bepler.
N Engl J Med, 2007 Feb 23; 356(8). PMID: 17314339
Highly Cited.
Genomic approaches to outcome prediction in prostate cancer.
Phillip G Febbo.
Cancer, 2009 Jun 23; 115(13 Suppl). PMID: 19544546
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Eli Rosenbaum, Mohammad Obaidul Hoque, +5 authors, David Sidransky.
Clin Cancer Res, 2005 Dec 03; 11(23). PMID: 16322291
A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.
Anil Potti, Sayan Mukherjee, +10 authors, Joseph R Nevins.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899777
Highly Cited.
Cancer statistics, 2009.
Ahmedin Jemal, Rebecca Siegel, +3 authors, Michael J Thun.
CA Cancer J Clin, 2009 May 29; 59(4). PMID: 19474385
Highly Cited.
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
Christine A Iacobuzio-Donahue, Baojin Fu, +17 authors, Daniel Laheru.
J Clin Oncol, 2009 Mar 11; 27(11). PMID: 19273710    Free PMC article.
Highly Cited.
Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer.
Martha L Slattery, Karen Curtin, +5 authors, Wade S Samowitz.
Int J Cancer, 2006 Nov 11; 120(3). PMID: 17096326
The hallmarks of cancer.
D Hanahan, R A Weinberg.
Cell, 2000 Jan 27; 100(1). PMID: 10647931
Highly Cited. Review.
A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.
Katherine S Garman, Chaitanya R Acharya, +13 authors, Anil Potti.
Proc Natl Acad Sci U S A, 2008 Dec 04; 105(49). PMID: 19050079    Free PMC article.
KRAS mutations in non-small cell lung cancer.
Gregory J Riely, Jenifer Marks, William Pao.
Proc Am Thorac Soc, 2009 Apr 08; 6(2). PMID: 19349489
Highly Cited. Review.
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
Michael W Kattan, Shahrokh F Shariat, +8 authors, Kevin M Slawin.
J Clin Oncol, 2003 Aug 13; 21(19). PMID: 12913106
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, +10 authors, Steven Narod.
J Clin Oncol, 2009 Dec 17; 28(3). PMID: 20008645
Highly Cited.
Advanced pancreatic ductal cancer: fibrotic focus and beta-catenin expression correlate with outcome.
Ichiro Watanabe, Takahiro Hasebe, +6 authors, Taira Kinoshita.
Pancreas, 2003 Apr 30; 26(4). PMID: 12717263
Gene expression predictors in breast cancer: current status, limitations and perspectives.
C Desmedt, E Ruíz-García, F André.
Eur J Cancer, 2008 Nov 04; 44(18). PMID: 18977656
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.
Li-Yan Khor, Michelle Desilvio, +8 authors, Radiation Therapy Oncology Group.
Cancer, 2005 Jul 12; 104(5). PMID: 16007688
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Gad Rennert, Shantih Bisland-Naggan, +4 authors, Steven A Narod.
N Engl J Med, 2007 Jul 13; 357(2). PMID: 17625123
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Mismatch repair and treatment resistance in ovarian cancer.
Jozien Helleman, Iris L van Staveren, +6 authors, Els M J J Berns.
BMC Cancer, 2006 Aug 02; 6. PMID: 16879751    Free PMC article.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, +12 authors, Johann S de Bono.
N Engl J Med, 2009 Jun 26; 361(2). PMID: 19553641
Highly Cited.
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Daniel R Rhodes, Martin G Sanda, +2 authors, Mark A Rubin.
J Natl Cancer Inst, 2003 May 08; 95(9). PMID: 12734317
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
J P Koivunen, J Kim, +13 authors, P A Jänne.
Br J Cancer, 2008 Jul 03; 99(2). PMID: 18594528    Free PMC article.
Recurrent gene fusions in prostate cancer.
Chandan Kumar-Sinha, Scott A Tomlins, Arul M Chinnaiyan.
Nat Rev Cancer, 2008 Jun 20; 8(7). PMID: 18563191    Free PMC article.
Highly Cited. Review.
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Christine M Ribic, Daniel J Sargent, +10 authors, Steven Gallinger.
N Engl J Med, 2003 Jul 18; 349(3). PMID: 12867608    Free PMC article.
Highly Cited.
The genetic attributable risk of breast and ovarian cancer.
E B Claus, J M Schildkraut, W D Thompson, N J Risch.
Cancer, 1996 Jun 01; 77(11). PMID: 8635102
Highly Cited.
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Anna Potapova, Amanda M Hoffman, +2 authors, Paul Cairns.
Cancer Res, 2008 Feb 19; 68(4). PMID: 18281473
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Yang Zong, Li Xin, +3 authors, Owen N Witte.
Proc Natl Acad Sci U S A, 2009 Jul 14; 106(30). PMID: 19592505    Free PMC article.
Highly Cited.
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Yixin Wang, Tim Jatkoe, +5 authors, David Atkins.
J Clin Oncol, 2004 Mar 31; 22(9). PMID: 15051756
Highly Cited.
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
B Iacopetta, A Russo, +62 authors, TP53-CRC Collaborative Group.
Ann Oncol, 2006 Mar 10; 17(5). PMID: 16524972
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
S Rajpar, C Massard, +8 authors, K Fizazi.
Ann Oncol, 2010 Feb 26; 21(9). PMID: 20181574
Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
Lorenzo Richiardi, Valentina Fiano, +5 authors, Franco Merletti.
J Clin Oncol, 2009 May 28; 27(19). PMID: 19470943
Molecular origins of cancer: Molecular basis of colorectal cancer.
Sanford D Markowitz, Monica M Bertagnolli.
N Engl J Med, 2009 Dec 19; 361(25). PMID: 20018966    Free PMC article.
Highly Cited. Review.
The polycomb group protein EZH2 is involved in progression of prostate cancer.
Sooryanarayana Varambally, Saravana M Dhanasekaran, +9 authors, Arul M Chinnaiyan.
Nature, 2002 Oct 11; 419(6907). PMID: 12374981
Highly Cited.
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Jason Madore, Fengge Ren, +6 authors, Anne-Marie Mes-Masson.
J Pathol, 2009 Dec 08; 220(3). PMID: 19967725
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Manuel Cobo, Dolores Isla, +17 authors, Rafael Rosell.
J Clin Oncol, 2007 Jul 03; 25(19). PMID: 17602080
Highly Cited.
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
Gizeh Pérez-Tenorio, Liza Alkhori, +5 authors, Olle Stål.
Clin Cancer Res, 2007 Jun 19; 13(12). PMID: 17575221
Highly Cited.
Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
Mitch Dowsett, Anita K Dunbier.
Clin Cancer Res, 2008 Dec 18; 14(24). PMID: 19088018
The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Pascal Sève, Tony Reiman, Charles Dumontet.
Lung Cancer, 2009 Oct 16; 67(2). PMID: 19828208
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
David A Eberhard, Bruce E Johnson, +16 authors, Kenneth J Hillan.
J Clin Oncol, 2005 Jul 27; 23(25). PMID: 16043828
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.
Tohru Nakagawa, Thomas M Kollmeyer, +7 authors, Robert B Jenkins.
PLoS One, 2008 Oct 11; 3(5). PMID: 18846227    Free PMC article.
Genetic instability in colorectal cancers.
C Lengauer, K W Kinzler, B Vogelstein.
Nature, 1997 Apr 10; 386(6625). PMID: 9121588
Highly Cited.
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, +15 authors, A John Iafrate.
J Clin Oncol, 2009 Aug 12; 27(26). PMID: 19667264    Free PMC article.
Highly Cited.
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Chang-Qi Zhu, Gilda da Cunha Santos, +12 authors, National Cancer Institute of Canada Clinical Trials Group Study BR.21.
J Clin Oncol, 2008 Jul 16; 26(26). PMID: 18626007
Highly Cited.
Genetic prognostic and predictive markers in colorectal cancer.
Axel Walther, Elaine Johnstone, +3 authors, David Kerr.
Nat Rev Cancer, 2009 Jun 19; 9(7). PMID: 19536109
Highly Cited. Review.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P Look, Wim L J van Putten, +37 authors, John A Foekens.
J Natl Cancer Inst, 2002 Jan 17; 94(2). PMID: 11792750
Highly Cited.
Prostate cancer genomics: towards a new understanding.
John S Witte.
Nat Rev Genet, 2008 Dec 24; 10(2). PMID: 19104501    Free PMC article.
Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
S L Lim, P Smith, +6 authors, J A Green.
Br J Cancer, 2008 Apr 17; 98(8). PMID: 18414472    Free PMC article.
Biomolecular markers of outcome prediction in prostate cancer.
Alessia Lopergolo, Nadia Zaffaroni.
Cancer, 2009 Jun 23; 115(13 Suppl). PMID: 19544547
Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.
Shuji Ogino, Katsuhiko Nosho, +5 authors, Charles S Fuchs.
J Clin Oncol, 2009 Aug 26; 27(27). PMID: 19704056    Free PMC article.
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Matthew J Ellis, Li Lin, +15 authors, José Baselga.
Breast Cancer Res Treat, 2009 Oct 22; 119(2). PMID: 19844788    Free PMC article.
Molecular predictive and prognostic markers in non-small-cell lung cancer.
Linda E Coate, Thomas John, Ming-Sound Tsao, Frances A Shepherd.
Lancet Oncol, 2009 Oct 03; 10(10). PMID: 19796752
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Maurizio Scaltriti, Federico Rojo, +8 authors, José Baselga.
J Natl Cancer Inst, 2007 Apr 19; 99(8). PMID: 17440164
Highly Cited.
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
Mary-Ellen Taplin, Barur Rajeshkumar, +9 authors, Cancer and Leukemia Group B Study 9663.
J Clin Oncol, 2003 Jul 16; 21(14). PMID: 12860943
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.
M W Kattan, T M Wheeler, P T Scardino.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334537
Highly Cited.
First-generation genomic tests for breast cancer treatment.
Fabrice Andre, Suzette Delaloge.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005177
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Karim Fizazi, Philippe Beuzeboc, +10 authors, Agnes Laplanche.
J Clin Oncol, 2009 Apr 15; 27(15). PMID: 19364971
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.
M Varella-Garcia, J Diebold, +8 authors, F Cappuzzo.
J Clin Pathol, 2009 Oct 29; 62(11). PMID: 19861557    Free PMC article.
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Allan Lipton, S M Ali, +9 authors, J Allard.
J Clin Oncol, 2002 Mar 16; 20(6). PMID: 11896093
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
Ugo De Giorgi, Vicente Valero, +12 authors, Massimo Cristofanilli.
J Clin Oncol, 2009 May 20; 27(20). PMID: 19451443
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
F P O'Malley, S Chia, +5 authors, K I Pritchard.
J Natl Cancer Inst, 2009 Apr 30; 101(9). PMID: 19401546    Free PMC article.
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Montserrat Sanchez-Cespedes, Paola Parrella, +6 authors, David Sidransky.
Cancer Res, 2002 Jul 05; 62(13). PMID: 12097271
Highly Cited.
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
J Domingo-Domenech, P L Fernandez, +7 authors, B Mellado.
Ann Oncol, 2007 Nov 14; 19(2). PMID: 17998285
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
Andrew J Stephenson, Peter T Scardino, +6 authors, Michael W Kattan.
J Clin Oncol, 2005 Sep 30; 23(28). PMID: 16192588    Free PMC article.
Highly Cited.
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Rita Nahta, Dihua Yu, +2 authors, Francisco J Esteva.
Nat Clin Pract Oncol, 2006 May 10; 3(5). PMID: 16683005
Highly Cited. Review.
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Lyndsay N Harris, Gloria Broadwater, +11 authors, Lynn Dressler.
J Clin Oncol, 2009 May 28; 27(21). PMID: 19470942    Free PMC article.
beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.
C Gamallo, J Palacios, +3 authors, A Armas.
Am J Pathol, 1999 Aug 06; 155(2). PMID: 10433945    Free PMC article.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.
P de Graeff, J Hall, +9 authors, A G J van der Zee.
Br J Cancer, 2006 Aug 02; 95(5). PMID: 16880779    Free PMC article.
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Joanne Edwards, Pamela Traynor, +3 authors, John M S Bartlett.
Clin Cancer Res, 2006 Jan 07; 12(1). PMID: 16397033
BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.
Rafael Rosell, Marcin Skrzypski, +12 authors, Jacek Jassem.
PLoS One, 2007 Nov 08; 2(11). PMID: 17987116    Free PMC article.
Proliferation marker Ki-67 in early breast cancer.
Ander Urruticoechea, Ian E Smith, Mitch Dowsett.
J Clin Oncol, 2005 Sep 30; 23(28). PMID: 16192605
Highly Cited. Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
The biology of ovarian cancer: new opportunities for translation.
Robert C Bast, Bryan Hennessy, Gordon B Mills.
Nat Rev Cancer, 2009 May 23; 9(6). PMID: 19461667    Free PMC article.
Highly Cited. Review.
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
M Colozza, E Azambuja, +3 authors, M J Piccart.
Ann Oncol, 2005 Jun 28; 16(11). PMID: 15980158
Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.
Alexandra F Leary, Wedad M Hanna, +5 authors, Mitch Dowsett.
J Clin Oncol, 2009 Mar 04; 27(10). PMID: 19255333
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, +15 authors, Hiroyuki Mano.
Nature, 2007 Jul 13; 448(7153). PMID: 17625570
Highly Cited.
BRAF mutation in metastatic colorectal cancer.
Jolien Tol, Iris D Nagtegaal, Cornelis J A Punt.
N Engl J Med, 2009 Jul 03; 361(1). PMID: 19571295
Highly Cited.
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
Gad Singer, Robert Oldt, +4 authors, Ie-Ming Shih.
J Natl Cancer Inst, 2003 Mar 20; 95(6). PMID: 12644542
Highly Cited.
A five-gene signature and clinical outcome in non-small-cell lung cancer.
Hsuan-Yu Chen, Sung-Liang Yu, +14 authors, Pan-Chyr Yang.
N Engl J Med, 2007 Jan 05; 356(1). PMID: 17202451
Highly Cited.
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
Matthew R Cooperberg, Jeanette M Broering, Peter R Carroll.
J Natl Cancer Inst, 2009 Jun 11; 101(12). PMID: 19509351    Free PMC article.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
F Jänicke, A Prechtl, +8 authors, German N0 Study Group.
J Natl Cancer Inst, 2001 Jun 21; 93(12). PMID: 11416112
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Juan-Miguel Mosquera, Rohit Mehra, +13 authors, Martin G Sanda.
Clin Cancer Res, 2009 Jul 09; 15(14). PMID: 19584163    Free PMC article.
Translational Medicine is developing in China: a new venue for collaboration.
Xiangdong Wang, Ena Wang, Francesco M Marincola.
J Transl Med, 2011 Jan 06; 9. PMID: 21205297    Free PMC article.
Methodological and practical challenges for personalized cancer therapies.
Ignacio I Wistuba, Juri G Gelovani, +2 authors, Roy S Herbst.
Nat Rev Clin Oncol, 2011 Mar 03; 8(3). PMID: 21364686
Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.
Josep M Llovet, Valerie Paradis, Masatoshi Kudo, Jessica Zucman-Rossi.
Liver Transpl, 2011 May 20; 17 Suppl 2. PMID: 21594967    Free PMC article.
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.
Fortunato Ciardiello, Sabine Tejpar, +4 authors, Eric Van Cutsem.
Target Oncol, 2011 Jun 02; 6(3). PMID: 21630045
Novel PI3K/Akt inhibitors screened by the cytoprotective function of human immunodeficiency virus type 1 Tat.
Yuri Kim, Joseph A Hollenbaugh, Dong-Hyun Kim, Baek Kim.
PLoS One, 2011 Jul 19; 6(7). PMID: 21765914    Free PMC article.
Prognostic biomarkers in ovarian cancer.
Jie Huang, Wei Hu, Anil K Sood.
Cancer Biomark, 2010 Jan 01; 8(4-5). PMID: 22045356    Free PMC article.
IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation.
Hernan Roca, Matthew J Craig, +8 authors, Kenneth J Pienta.
J Cell Biochem, 2011 Dec 17; 113(5). PMID: 22174091    Free PMC article.
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase.
Hongdo Do, Alexander Dobrovic.
Oncotarget, 2012 May 31; 3(5). PMID: 22643842    Free PMC article.
MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
S T Guo, C C Jiang, +10 authors, X D Zhang.
Oncogene, 2012 Jun 20; 32(15). PMID: 22710713    Free PMC article.
Highly Cited.
Hemopexin as biomarkers for analyzing the biological responses associated with exposure to silica nanoparticles.
Kazuma Higashisaka, Yasuo Yoshioka, +12 authors, Yasuo Tsutsumi.
Nanoscale Res Lett, 2012 Oct 09; 7(1). PMID: 23039107    Free PMC article.
ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.
Alec Vaezi, Chelsea H Feldman, Laura J Niedernhofer.
Pharmgenomics Pers Med, 2011 Jan 01; 4. PMID: 23226053    Free PMC article.
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.
Yan Ye, Lei Jin, +18 authors, Xu Dong Zhang.
Nat Commun, 2013 Feb 28; 4. PMID: 23443536    Free PMC article.
Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
Ágnes Márk, Melinda Hajdu, +8 authors, Anna Sebestyén.
BMC Cancer, 2013 May 23; 13. PMID: 23693095    Free PMC article.
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology.
Charles Ferté, Andrew D Trister, +8 authors, Stephen H Friend.
Clin Cancer Res, 2013 Jun 20; 19(16). PMID: 23780890    Free PMC article.
Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.
Yan Ye, Qun Li, +5 authors, Sen Yang.
Transl Oncol, 2013 Aug 03; 6(4). PMID: 23908690    Free PMC article.
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
Sing Yu Moorcraft, Elizabeth C Smyth, David Cunningham.
Therap Adv Gastroenterol, 2013 Sep 05; 6(5). PMID: 24003339    Free PMC article.
LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.
Zhiheng Chen, Li Yang, +4 authors, Zuocheng Yang.
Mol Cell Biochem, 2013 Sep 28; 385(1-2). PMID: 24072614
Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma.
Xiaosheng Fang, Xiangxiang Zhou, Xin Wang.
Biomark Res, 2013 Nov 21; 1(1). PMID: 24252186    Free PMC article.
Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors.
Hidemi Rikiishi.
Cancers (Basel), 2010 Jan 01; 2(4). PMID: 24281216    Free PMC article.
Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data.
In Sock Jang, Elias Chaibub Neto, +2 authors, Adam A Margolin.
Pac Symp Biocomput, 2013 Dec 04;. PMID: 24297534    Free PMC article.
Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.
Stephen Q Wong, Jason Li, +5 authors, Alexander Dobrovic.
Sci Rep, 2013 Dec 18; 3. PMID: 24336498    Free PMC article.
CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis.
Qiang Ding, Yumi Miyazaki, +3 authors, Sonshin Takao.
Mol Cancer, 2014 Jan 29; 13. PMID: 24468059    Free PMC article.
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
Daoud Sie, Peter J F Snijders, +11 authors, Daniëlle A M Heideman.
Cell Oncol (Dordr), 2014 Sep 12; 37(5). PMID: 25209392
The importance of autophagy regulation in breast cancer development and treatment.
Joanna Magdalena Zarzynska.
Biomed Res Int, 2014 Oct 16; 2014. PMID: 25317422    Free PMC article.
Prediction of individual response to anticancer therapy: historical and future perspectives.
Florian T Unger, Irene Witte, Kerstin A David.
Cell Mol Life Sci, 2014 Nov 13; 72(4). PMID: 25387856    Free PMC article.
TrkC expression predicts favorable clinical outcome in invasive ductal carcinoma of breast independent of NT-3 expression.
Wei Zhang, Zhi-Chun Lin, +4 authors, Yun Niu.
Am J Cancer Res, 2014 Dec 19; 4(6). PMID: 25520870    Free PMC article.
Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors.
In Sock Jang, Rodrigo Dienstmann, Adam A Margolin, Justin Guinney.
Pac Symp Biocomput, 2015 Jan 17;. PMID: 25592566    Free PMC article.
Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions.
Jeremy R Huddy, Melody Z Ni, Sheraz R Markar, George B Hanna.
World J Gastroenterol, 2015 Apr 22; 21(14). PMID: 25892860    Free PMC article.
Automated Analysis and Classification of Histological Tissue Features by Multi-Dimensional Microscopic Molecular Profiling.
Daniel P Riordan, Sushama Varma, Robert B West, Patrick O Brown.
PLoS One, 2015 Jul 16; 10(7). PMID: 26176839    Free PMC article.
INPP4B is an oncogenic regulator in human colon cancer.
S T Guo, M N Chi, +21 authors, C C Jiang.
Oncogene, 2015 Sep 29; 35(23). PMID: 26411369    Free PMC article.
Locus-specific gene repositioning in prostate cancer.
Marc Leshner, Michelle Devine, +3 authors, Karen J Meaburn.
Mol Biol Cell, 2015 Nov 14; 27(2). PMID: 26564800    Free PMC article.
INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.
Meng Na Chi, Su Tang Guo, +12 authors, Xu Dong Zhang.
Oncotarget, 2015 Nov 18; 6(37). PMID: 26573229    Free PMC article.
UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.
Xuechao Wan, Shu Yang, +6 authors, Yao Li.
J Exp Clin Cancer Res, 2016 Feb 18; 35. PMID: 26884069    Free PMC article.
Spatial Genome Organization and Its Emerging Role as a Potential Diagnosis Tool.
Karen J Meaburn.
Front Genet, 2016 Aug 11; 7. PMID: 27507988    Free PMC article.
Ergosterol peroxide inhibits ovarian cancer cell growth through multiple pathways.
Weiwei Tan, Meihong Pan, +3 authors, Hongda Liu.
Onco Targets Ther, 2017 Aug 02; 10. PMID: 28761355    Free PMC article.
Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine.
Maria Jeppesen, Grith Hagel, +6 authors, Jacob Thastrup.
PLoS One, 2017 Sep 07; 12(9). PMID: 28877221    Free PMC article.
Targetable Clinical Nanoparticles for Precision Cancer Therapy Based on Disease-Specific Molecular Inflection Points.
Charalambos Kaittanis, Alexander Bolaender, +3 authors, Jan Grimm.
Nano Lett, 2017 Oct 17; 17(11). PMID: 29035540    Free PMC article.
A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer.
Chin-Ann J Ong, Nicholas B Shannon, +15 authors, N Gopalakrishna Iyer.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108335    Free PMC article.
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.
Charalambos Kaittanis, Chrysafis Andreou, +14 authors, Jan Grimm.
J Exp Med, 2017 Nov 17; 215(1). PMID: 29141866    Free PMC article.
Blank spots on the map: some current questions on nuclear organization and genome architecture.
Carmen Adriaens, Leonid A Serebryannyy, +10 authors, Tom Misteli.
Histochem Cell Biol, 2018 Sep 22; 150(6). PMID: 30238154    Free PMC article.
Decreased cytoplasmic expression of Raptor correlates with disease progression and unfavorable prognosis in hepatocellular carcinoma.
Shisi Huang, Xian Lin, +3 authors, Rongcheng Luo.
Int J Clin Exp Pathol, 2017 Dec 01; 10(12). PMID: 31966542    Free PMC article.
Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo.
Lu Zhang, Di Jing, +10 authors, Kit S Lam.
Nat Nanotechnol, 2020 Jan 29; 15(2). PMID: 31988501    Free PMC article.
Investigating Programmed Cell Death and Tumor Invasion in a Three-Dimensional (3D) Microfluidic Model of Glioblastoma.
Ehsan Samiei, Amir Seyfoori, +2 authors, Mohsen Akbari.
Int J Mol Sci, 2020 May 06; 21(9). PMID: 32365781    Free PMC article.
Lung and Abdominal Biopsies in the Age of Precision Medicine.
Leonard Dalag, Jonathan K Fergus, Steven M Zangan.
Semin Intervent Radiol, 2019 Aug 23; 36(3). PMID: 31435134    Free PMC article.
CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p/E2F1 axis.
Jing Zhou, Ze-Ning Dong, +5 authors, Yu-Fang Sun.
Aging (Albany NY), 2020 Jul 16; 12(14). PMID: 32668414    Free PMC article.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Frances Humby, Patrick Durez, +28 authors, R4RA collaborative group.
Lancet, 2021 Jan 25; 397(10271). PMID: 33485455    Free PMC article.